CureVac, Bayer partner on COVID-19 vaccine

By The Science Advisory Board staff writers

January 8, 2021 -- CureVac and Bayer have signed a collaboration and services agreement to develop a new class of medicines based on messenger RNA (mRNA), starting with CureVac's COVID-19 vaccine candidate, CVnCoV.

Bayer will contribute its expertise and infrastructure toward clinical operations, regulatory affairs, pharmacovigilance, medical information, and supply chain performance in selected countries.

CureVac will be the marketing authorization holder while Bayer will support CureVac with country operations within the European Union and selected additional markets. Bayer holds further options to become the marketing authorization holder in markets outside of Europe.

No financial terms of the agreement were disclosed.

Bayer, Atara collaborate on CAR T-cell therapies
Bayer and Atara Biotherapeutics have entered into an agreement to research, develop, manufacture, and license mesothelin-directed chimeric antigen receptor...
EU secures 225M doses of CureVac COVID-19 vaccine
The European Commission approved a fifth contract with CureVac for the initial purchase of 225 million doses on behalf of all European Union (EU)...
Bayer acquires Asklepios to advance gene therapies
Bayer has agreed to pay $2 billion to acquire Asklepios BioPharmaceutical, a U.S.-based biotechnology company specializing in gene therapies.
Specifica transfers antibody discovery platform to Bayer
Specifica announced the transfer of its Generation 3 antibody libraries to Bayer under an agreement that will enable the company to develop antibody-based...
CEPI, Clover to partner on COVID-19 vaccine
The Coalition for Epidemic Preparedness Innovations (CEPI) and Clover Biopharmaceuticals Australia plan to partner on the development of a COVID-19 vaccine.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter